Raltegravir-based regimen versus raltegravir-based regimen plus atorvastatin for reducing ?inflamaging? (aging-related complication) in HIV-infected patients older than 60 years.

Fundació Lluita contra la SIDA0 个研究点目标入组 60 人开始时间: 2015年7月31日最近更新: 2018年7月23日

试验速览

暂无简介。

•1. Patient having a diagnosis of HIV-1 infection.
•2. Age higher or equal to 60 years old.
•3. Current HAART including Truvadaâ or Kivexaâ plus a ritonavir boosted PI started at least 6 months before.
•4. Maintained undetectable plasma HIV-1 RNA (VL < 50 copies/mL) for at least 12 months.
•5. Voluntary written informed consent.
•6. In women of childbearing age, commitment to use barrier contraceptive method throughout the study.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 60
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 60

•1. History of virological failure to integrase inhibitors.
•2. Suspected or documented resistance mutations to the integrase, as well as NRTI?related mutations that may impact nucleoside activity in current regimen.
•3. Systemic concurrent process such as coinfection with hepatitis C or B, acute systemic infection within the last 4 months, neoplasm, chronic inflammatory process, etc.
•4. Treatment with other drugs with anti-inflammatory, anticoagulant or antiplatelet effect (for instance corticosteroids, aspirin, etc?)
•5. Therapy with statins within the last 6 months.
•6. Pregnant or lactating women.

发起方

Fundació Lluita contra la SIDA